BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Ciprofibrate
,
rs2300478
,
SNCA
,
Metabolism of xenobiotics
,
Diabetes mellitus
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
MK 521
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for MK 521
Explore Curated Studies Results
Literature
Most Relevant Literature
Silibinin enhances anti-renal fibrosis effect of MK-521 via downregulation of TGF-β signaling pathwa…
Enalapril maleate and a lysine analogue (MK-521): disposition in man.
Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme in…
Acute hemodynamic and hormonal effects of lisinopril (MK-521) in congestive heart failure.
Acute Hemodynamic and Hormonal Effects of Mk-521 in Congestive Heart Failure.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Multiple Rising Dose Study of MK-6194 in Participants With Atopic Dermatitis (MK-6194-008)
Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Di…
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Dia…
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Montelukast (MK-0476) …
Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A0…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ